primary central nervous system lymphoma
Conditions
Interventions
central nervous system lymphoma group vs. non central nervous system lymphoma group:Nil
Sponsors
Huashan Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Establishing precise diagnosis system for primary CNS lymphoma (PCNSL): (1) No limit of sex or age; (2) Chinese participants were admitted; (3) Pathologly diagnosised as CNS lymphoma and enough Formalin-Fixed and Parrffin-Embedded(FFPE) left after diagnosis (4) Diagnosised as CNS lymphoma and performed whole exon sequencing(WES) by third party company; (5) Patients with related-refractory central nervous system lymphoma treated with conventional regimen or targeted therapy with Ibrutinib. (6) Fully understand the content of the study, can participate in the follow-up study behavior, I am willing to cooperate. 2. Exploring pathogenesis of PCNSL using integrated targeted visualization technology: (1) No limit of sex or age; (2) Chinese participants were admitted; (3) Imaging examination confirmed central nervous system occupation, suspected central nervous system lymphoma, and biopsy or tumor resection was proposed due to the condition; (4) the examination other diseases of the central nervous system lymphoma, such as epilepsy, trauma, deep brain tumors, cerebrovascular disease, etc., due to illness, in conjunction with the art of CLP physiological or surgical resection decompression, operation scope including tumor and a small number of brain tissue around the tumor, or because of illness need to remove part of the normal brain tissue of the patients; (5) Lymph node biopsy or tumor resection should be performed for lymphoma patients who are highly suspected of non-central involvement after physical examination, imaging examination and other examinations; (6) Peripheral diffuse large B lymphoma with no central nervous system invasion was confirmed; (7) Those who have a full understanding of the research content and are able to participate in the follow-up study and are willing to cooperate.
Exclusion criteria
Exclusion criteria: 1. Patients with severe cardiopulmonary diseases and abnormal coagulation function, which lead to the inability to tolerate the operational tests required to identify the disease; 2. Unqualified samples; 3. There is no residual after pathological tissue diagnosis; 4. Unwillingness to provide information and cooperate with follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| genomic variants;transcriptome change;overall survival;progression free survival; | — |
Countries
China
Contacts
Public ContactTong Chen
Huashan Hospital, Fudan University
Outcome results
None listed